Staar Surgical initiated with a Hold at Stifel

Stifel analyst Thomas Stephan initiated coverage of Staar Surgical with a Hold rating and $60 price target. His survey of 45 U.S. ophthalmologists already trained on the company’s recently-FDA approved EVO Implantable Collamer Lens was "mixed" and he thinks that the U.S. ramp may be slower than expected in both the intermediate term and long term, Stephan tells investors. He added that his survey work points to hurdles moving downstream, "muted procedure volume expectations," and market share targets that "could prove overly optimistic."